dacarbazine and imatinib mesylate
dacarbazine has been researched along with imatinib mesylate in 21 studies
Research
Studies (21)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (47.62) | 29.6817 |
2010's | 11 (52.38) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Patel, SR | 1 |
Fernandez, CV; Rigby, H; Schmidt, MH; Yu, W | 1 |
Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Reddiconto, G; Sica, S | 1 |
Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I | 1 |
Ezumi, K; Ikeda, M; Monden, M; Nomura, M; Sekimoto, M; Takemasa, I; Yamamoto, H | 1 |
Desjardins, A; Egorin, MJ; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; McLendon, R; Quinn, JA; Reardon, DA; Rich, JN; Salvado, AJ; Sathornsumetee, S; Vredenburgh, JJ | 1 |
Liau, LM; Salgaller, ML | 1 |
Furuhashi, M; Kawamura, T; Ogawa, Y; Shimada, S; Tsukamoto, K | 1 |
Aldrich, W; Dombos, C; Triozzi, PL | 1 |
Dresemann, G; Engel, E; Fluge, O; Heinrich, B; Hosius, C; Karup-Hansen, A; Krex, D; Mayer-Steinacker, R; Mehdorn, M; Nikolova, Z; Nowak, A; Olver, IN; Parker, R; Rosenthal, MA; Schleyer, E; Sieder, C; Sorenson, G; Steinbach, JP; Wagner, W; Wedding, U; Weller, M | 1 |
Schiff, D; van den Bent, MJ; Wen, PY | 1 |
Baldini, L; F, FG; Ferrario, A; Goldaniga, M; Olivero, B; Radaelli, F; Rossi, F | 1 |
Beery, E; Fenig, E; Gil-Ad, I; Israeli, M; Lahav, M; Nordenberg, J; Tzadok, S; Uziel, O; Weizman, A | 1 |
Aaberg-Jessen, C; Christensen, KG; Jensen, PH; Jensen, SS; Kolenda, J; Kristensen, BW; Nørregaard, A; Schrøder, HD | 1 |
Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L | 1 |
Classen, CF; Krohn, M; Linnebacher, M; Mullins, CS; Schneider, B; Stockhammer, F | 1 |
Aaron, M; Halperin, DM; Hoff, AO; Hoff, PM; Phan, AT; Yao, JC | 1 |
Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK | 1 |
Reviews
4 review(s) available for dacarbazine and imatinib mesylate
Article | Year |
---|---|
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
Emerging drugs for the treatment of soft tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Dacarbazine; Doxorubicin; Gastrointestinal Stromal Tumors; Humans; Ifosfamide; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sarcoma; Sunitinib | 2007 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
Trials
4 trial(s) available for dacarbazine and imatinib mesylate
Article | Year |
---|---|
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Mas; Pyrimidines; Temozolomide | 2008 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Other Studies
13 other study(ies) available for dacarbazine and imatinib mesylate
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate.
Topics: Angiomyolipoma; Antineoplastic Agents; Benzamides; Child; Dacarbazine; Epithelioid Cells; Fatal Outcome; Female; Humans; Imatinib Mesylate; Kidney Neoplasms; Neoplasm Metastasis; Piperazines; Pyrimidines; Treatment Failure | 2005 |
Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Temozolomide | 2005 |
Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dacarbazine; Doxorubicin; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Male; Mesentery; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction; Tamoxifen | 2008 |
Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Biological Transport, Active; Dacarbazine; Female; Imatinib Mesylate; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2008 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Humans; Imatinib Mesylate; Melanoma; Mice; Piperazines; Pyrimidines; Temozolomide; Uveal Neoplasms; Xenograft Model Antitumor Assays | 2008 |
ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Vinblastine | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Phenothiazines; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Psychotropic Drugs; Pyrimidines; Selective Serotonin Reuptake Inhibitors; Temozolomide | 2010 |
Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.
Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers; Carrier Proteins; Cell Death; Dacarbazine; Glial Fibrillary Acidic Protein; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Microtubule-Associated Proteins; Neuroglia; Neurons; Nimustine; Piperazines; Propidium; Pyrimidines; Rats; Temozolomide; Vincristine | 2012 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Computational Biology; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Glioblastoma; Humans; Imatinib Mesylate; Microarray Analysis; Piperazines; Pyrimidines; rac1 GTP-Binding Protein; Receptors, Notch; RNA, Neoplasm; Signal Transduction; Temozolomide | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cryopreservation; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Dosage; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Temozolomide; Tumor Cells, Cultured; Vincristine | 2013 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
A case series of anal melanoma including the results of treatment with imatinib in selected patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate | 2016 |